Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Journal of Clinical Medicine|December 9, 2023
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 StudyPablo Ryan, Helen Dolengevich-Segal, Luis Ramos-Ruperto, et al.
Open Forum Infectious Diseases|May 30, 2019
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1Juan Berenguer, José Luis Calleja, María Luisa Montes, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antiviralsMaría Sánchez-Azofra, Inmaculada Fernández, María L García-Buey, et al.
The New England Journal of Medicine|December 22, 2021
Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsRobert L Gottlieb, Carlos E Vaca, Roger Paredes, et al.
Biomedicines|November 27, 2021
Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV PatientsDaniel Valle-Millares, Óscar Brochado-Kith, Luz Martín-Carbonero, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 28, 2021
Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patientsDavid de Gonzalo-Calvo, Iván D Benítez, Lucía Pinilla, et al.
Hepatology (Baltimore, Md.)|January 30, 2018
All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findingsJuan Berenguer, Ángela Gil-Martin, Inmaculada Jarrin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2022
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Fernando de la Calle-Prieto, María Velasco, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Pageof 14